Quarterly ResultMay 14, 2026, 05:07 PM
Jupiter Neurosciences Q1 Net Loss $(2.06)M; Going Concern Doubt
AI Summary
Jupiter Neurosciences reported an increased net loss of $(2.06) million for the first quarter of 2026, up from $(1.53) million in the prior year, alongside a significant increase in its total stockholders' deficit. Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern. Additionally, the company received notices from Nasdaq regarding non-compliance with minimum bid price and market value requirements, facing potential delisting. The company generated initial product revenues of $18,652 and utilized its Standby Equity Purchase Agreement (SEPA) to raise $625,748 in net proceeds.
Key Highlights
- Management concluded substantial doubt about the Company's ability to continue as a going concern.
- Received Nasdaq notices for non-compliance with minimum bid price and market value requirements.
- Net loss increased to $(2,061,958) for Q1 2026 from $(1,528,867) in Q1 2025.
- Generated product revenues of $18,652 in Q1 2026, up from $0 in Q1 2025.
- Cash balance decreased to $2,362,749 as of March 31, 2026, from $3,789,342 at Dec 31, 2025.
- Total stockholders' deficit increased to $(2,783,457) from $(1,831,852) at Dec 31, 2025.
- Net cash used in operating activities was $(1,432,100) for Q1 2026.
- Issued ~1.1M shares via SEPA for net proceeds of $625,748 as of March 31, 2026.